Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Novel Method of O- Demethylation and N-Deprotection of Opioid Compounds
View Prospective Grant of Exclusive License: Synthesis of Medical Opiate Compounds
View Prospective Grant of Exclusive License: Therapeutic Polyamines
View Prospective Grant of Exclusive License: Immunotoxins With In-Vivo T Cell Suppressant Activity and Methods of Use and Immunotoxins
View Prospective Grant of Exclusive License: Pharmaceuticals for the Treatment of Autoimmune Disease and Transplant Rejection 6/07/93 (2) Method of Treating Autoimmune Diseases and Transplantation Rejection
View Opportunity for a Cooperative Research and Development Agreement
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Fusion Proteins That Include Antibody and Non-Antibody Portions In view of the important priority of developing new agents for the treatment or prevention of cancer, interested parties should notify this office in writing no later than October 18, 1996. Respondents will then be provided an additional 30 days for the filing of formal proposals.
View Opportunity for Licensing: Homologous Recombination and Cloning of DNA and Control of Gene Expression
View Prospective Grant of Exclusive License: Method of Treating Demyelinating Diseases With Insulin-Like Growth Factor I
View National Cancer Institute: Opportunities for Cooperative Research and Development Agreements (CRADA) for the Development of Green Fluorescent Protein (GFP) Technology Applications In view of the high interest for developing GFP for applications and diagnostics, interested parties should notify the NCI Office of Technology Development in writing no later than thirty (30) days from the date of this announcement. Respondents will then be provided an additional thirty (30) days for submitting formal CRADA proposals.
View Prospective Grant of Exclusive License: Gossypol Acetic Acid for the Treatment of Cancer
View Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Novel Heparin-Binding Peptides There is no deadline by which license applications must be received. CRADA proposals must be received on or before September 16, 1996.
View National Cancer Institute: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Hydroxylated Aromatic Protein Cross-Linking Compounds for the Treatment of Hyperproliferative Epithelial Lesions In view of the important priority of developing new agents for the treatment or prevention of cancer, interested parties should notify this office in writing no later than July 12, 1996. Respondents will then be provided an additional 30 days for the filing of formal proposals.
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Gene Therapy for Cancer and Restenosis Applications
View Prospective Grant of a Partial Exclusive License: Recombinant Heregulin PE-40 Toxin Cancer Therapeutics Which Bind to the Ligand Binding Site of the erbB3 and/or erbB4 Proteins
View National Institute of Environmental Health Sciences: Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Application of Highly Potent and Ultraselective greek-d Opioidmimetic Peptide Antagonists for Biochemical, Pharmacological, Clinical and Therapeutic Studies Capability statements must be received by NIH on, or before May 21, 1996.
View National Heart, Lung, and Blood Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of Lymphocyte ADP-Ribosyltransferase and its Corresponding Hydrolase as a Potential Target for Therapeutic Intervention in Diseases of the Immune System
View Prospective Grant of Exclusive License: Cartilage-Derived Morphogenetic Proteins
View Opportunity For Licensing: Sequence Modification of Oligonucleotide Primers to Manipulate Non-Templated Nucleotide Addition
View Prospective Grant of Exclusive License: Activity Dependent Neurotropic Factor
View National Institute of Allergy and Infectious Diseases: Licensing Opportunity and/or Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Development of Influenza A PB2 Gene Technology License applications must be received on or before March 11, 1996. CRADA proposals should be received on or before April 11, 1996 for priority consideration. However, CRADA proposals submitted thereafter will be considered until a suitable CRADA Collaborator is selected.
View Prospective Grant of Exclusive License: Antibacterial Therapy With Bacteriophage Genotypically Modified to Delay Inactivation by the Host Defense System
View Prospective Grant of Exclusive License: Biomedical Uses of CPX (8-Cyclopentyl-1,3-Dipropylxanthine) and Related Compounds for Cystic Fibrosis and Other Human Diseases
View Prospective Grant of Exclusive License: Melanoma Antigens and Their Use in Diagnostic and Therapeutic Methods